Research digest / Questions
CJC-1295, answered from the published record
The questions people actually ask about CJC-1295 — safety, FDA status, side effects, testosterone, the DAC distinction — answered directly and cited where the answer turns on a number.
Is CJC-1295 safe?
CJC-1295 is not approved for human use and large safety trials do not exist; theoretical concerns include fluid retention, effects on insulin sensitivity, and IGF-1 epidemiology, and FDA briefing materials cited immunogenicity [1]. Published human data are limited to early-phase pharmacokinetic studies, so 'safe' cannot be established from the record. The honest position is an absence of long-term human safety data, not a clean bill [1].
Are CJC-1295 peptides safe?
There are no large or long-term human safety trials; published human data are limited to early PK studies, and theoretical concerns — fluid retention, insulin sensitivity, IGF-1 epidemiology, immunogenicity — remain unresolved [1]. The molecule's GH/IGF-1 effects are well characterized over days; its safety over months or years in healthy adults is simply not in the literature [1].
What are the side effects of CJC-1295?
Reported and theoretical concerns include fluid retention and edema (GH-driven sodium reabsorption), effects on insulin sensitivity, IGF-1 epidemiology linked to some cancer risk, and immunogenicity flagged in FDA briefing materials [12]. These track the GH/IGF-1 axis the molecule activates [1]. None are quantified as CJC-1295 trial outcomes, because the controlled human safety data needed to quantify them do not exist [1].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog acting on the GHRH receptor to stimulate growth-hormone release; it is not an anabolic steroid and has a different mechanism and chemistry [2]. Steroids are lipid-based hormones acting on nuclear receptors; CJC-1295 is a 29-residue peptide acting on a cell-surface G-protein-coupled receptor [2].
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use by the FDA or any major regulator; it is handled as an unapproved research chemical and was not recommended for the FDA 503A compounding bulks list [1]. The DAC development program was discontinued, and no approved human indication exists [1].
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; the published CJC-1295 literature does not establish a direct effect on testosterone [1]. Its characterized activity is stimulation of growth hormone and IGF-1, a separate hormonal pathway from androgen production [3].
Does CJC-1295 lower testosterone?
The published CJC-1295 literature does not document a lowering of testosterone; its characterized effects are on the GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal axis [1]. No study in the record establishes a testosterone-suppressing effect [3].
Does CJC-1295 raise testosterone?
No published CJC-1295 study establishes a rise in testosterone; CJC-1295's documented activity is stimulation of growth hormone and IGF-1, not androgen production [1][3]. The molecule's mechanism runs through the GHRH receptor and the GH/IGF-1 axis, which is not the androgen pathway [2].
Are peptides safer than TRT?
This cannot be answered from the CJC-1295 evidence base: CJC-1295 is unapproved with no comparative safety trials, whereas testosterone replacement is a regulated therapy; the two are not directly compared in the literature [1]. Any 'safer than' claim about CJC-1295 versus a regulated therapy lacks the head-to-head data to support it [1].
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent albumin conjugation for a multi-day half-life [1][2]. The no-DAC form keeps the substitutions but is short-acting [12].
What does CJC-1295 do?
It binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1; in human studies it elevated GH and IGF-1 for days after a single dose [1][3]. Notably, GH pulsatility was preserved under the sustained stimulation [3].
What to expect when taking CJC-1295?
In human studies CJC-1295 raised mean GH and IGF-1 for days after a single subcutaneous dose while preserving GH pulsatility; this describes research findings, not a human-use outcome or recommendation [1][3]. The documented response is a multi-day elevation of the GH/IGF-1 axis at the doses studied [1].
What is CJC-1295 with DAC?
The DAC ('Drug Affinity Complex') version functionalizes a C-terminal lysine so the peptide covalently binds Cys34 of serum albumin, extending the plasma half-life toward that of albumin itself [2]. This is what makes the DAC form long-acting, distinct from the short-acting no-DAC form [12].
What is CJC-1295 DAC?
CJC-1295 DAC is the long-acting form: the tetrasubstituted hGRF(1-29) sequence plus an albumin-binding moiety, giving a multi-day half-life, distinct from the short-acting no-DAC 'Modified GRF 1-29' [1][2][12]. Its 5.8-8.1 day half-life was characterized in healthy adults [1].
How much CJC-1295 should I take?
Human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram; there is no established human therapeutic dose, as CJC-1295 is an unapproved research chemical [1][3]. The study doses describe how the kinetics were measured, not a regimen.
How much CJC-1295 DAC should I take?
Human PK studies of the DAC variant used 30, 60 or 90 micrograms per kilogram subcutaneously; community fixed-dose 'protocols' are not derived from controlled human trials and there is no established human dose [1][3]. No regulator has set a human dose for CJC-1295 DAC [1].
How much CJC-1295 / ipamorelin should I take?
No controlled human trial established a CJC-1295/ipamorelin dose; the pairing is studied for two-receptor (GHRH + GHRP) synergy, but circulating fixed-dose protocols are not trial-derived [11]. The mechanism is grounded; a validated human dose is not part of the record [11].
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [1]. This describes laboratory methodology, not a human-use preparation step.
Where to inject CJC-1295?
Subcutaneous injection was the primary route in published studies (intravenous was used in early GRF(1-29) PK work); this describes research methodology, not a human-use recommendation [1][9]. The multi-day human kinetics were characterized by the subcutaneous route [1].
How long does CJC-1295 stay in the body?
CJC-1295 DAC had an estimated half-life of 5.8-8.1 days in healthy adults, with IGF-1 elevation persisting up to 28 days after multiple doses; the no-DAC Modified GRF (1-29) form is short-acting (minutes-to-hours) [1][12]. The answer depends on which form, and the two differ enormously [2][12].
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs act through distinct receptors and synergize, producing GH release greater than either alone; this two-pathway rationale is the basis for pairing them, though human efficacy data for the combination are limited [11]. The mechanism is firmer than the controlled-trial evidence [11].
What is CJC-1295 ipamorelin?
It is the research combination of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin), pairing two complementary pathways that drive growth-hormone release [11]. The two act on distinct receptors, which is why they are studied together [11].